Newsroom

June 2016

• Press release Jun 28, 2016

  Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor

  Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
• 
  Story Jun 24, 2016 From Our Labs

  Tuning drugs to succeed on the cell’s surface

  Researchers improve our understanding about how compounds bind to proteins in the cell membrane—and the membrane itself.

• Press release Jun 22, 2016

  Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

  Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1]   Cardiology experts…
• In The News Jun 21, 2016

  Expanding access to healthcare: What will it really take?

  Head of global nonprofit PATH explores how “social innovation” such as the Novartis Access program is helping expand access to healthcare in some of the world’s poorest countries.
• In The News Jun 20, 2016

  Malaria's deadly comeback

  In an editorial for Project Syndicate, Nick White, Professor of Tropical Medicine at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, and Thierry Diagana, Head of the Novartis Institute…
• 
  Story Jun 16, 2016 Discovery

  Tackling the common denominator in liver disease

  Researchers focus on reversing the scarring that’s common to liver diseases.

• 
  Story Jun 15, 2016 Patient Perspectives

  Migraine: One of the world’s most common diseases

  Did you know migraine is the most common of all neurological disorders? Learn more surprising facts.

• Press release Jun 15, 2016

  Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

  Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
• Press release Jun 15, 2016

  Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation

  Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
• Press release Jun 15, 2016

  Novartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéen

  Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
• Press release Jun 10, 2016

  Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder

  EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
• Press release Jun 10, 2016

  Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

  Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1]  RESPONSE-2 complements data…